Genmab GMAB 深 沪
交易中 10-06 11:18:27 美东时间
37.48
-1.000
-2.60%
华盛通- 最 高40.17
- 今 开39.11
- 成交量 33.49万股
- 最 低 32.21
- 昨 收 38.48
- 总市值 2454.94万
- 52周最高 40.17
- 市盈率 静 51.78
- 换手率 51.13%
- 52周最低 23.62
- 委 比 7.32%
- 总股本 0.01亿
- 历史最高 49.07
- 量 比 0.21
- 振 幅 20.69%
- 历史最低 1.10
- 每 手 1
- 风险率 2.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
Curis shares positive updated clinical data for emavusertib and increases its year-end guidance for the TakeAim CLL study.
07-23 01:04
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label expansion and future growth opportunities.
07-01 00:31
ADC没有冬天，但一半的人已经穿上棉袄
本文系基于公开资料撰写，仅作为信息交流之用，不构成任何投资建议 一份榜单，两个世界。 2026年Q1，Enhertu单季增长34%，阿斯利康口径...
05-21 07:29
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge
Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck cancer opportunity and obesity pipeline.
04-07 23:56
Genmab Announces 725M DKK Buyback Plan
https://ml-eu.globenewswire.com/Resource/Download/9b555715-1796-4b46-9292-00131c863e68
02-18 04:28
Genmab Cancer Drug DARZALEX Posts $14.4B in Global Sales in 2025
Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename
01-21 19:27
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
Incyte reported positive results from a trial of tafasitamab as a first-line treatment for adults with DLBCL. No new safety issues were seen.
01-06 00:59
Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets
Genmab will discontinue clinical development of acasunlimab to focus on more promising late-stage programs in its portfolio.
2025-12-30 01:32
Genmab A/S Plans To Discontinue Further Clinical Development Of Acasunlimab
Genmab A/S (NASDAQ:GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab's strategic focus on the most value‑creating opportunities in its
2025-12-29 21:17
Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval
FDA approves Breyanzi, a CAR T cell therapy for relapsed or refractory marginal zone lymphoma. It has a high response rate.
2025-12-05 21:36
